DelveInsight’s, “Chronic Myelomonocytic Leukaemia Pipeline Insight 2023” report provides comprehensive insights about 25+ Chronic Myelomonocytic Leukaemia companies and 25+ pipeline drugs in the Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the Chronic Myelomonocytic Leukaemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myelomonocytic Leukaemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report
- DelveInsight’s Chronic Myelomonocytic Leukaemia pipeline report depicts a robust space with 25+ Chronic Myelomonocytic Leukaemia companies working to develop 25+ pipeline therapies for Chronic Myelomonocytic Leukaemia treatment.
- The leading Chronic Myelomonocytic Leukaemia Companies working in the market include Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc., and others.
- Promising Chronic Myelomonocytic Leukaemia Pipeline Therapies in the various stages of development include lenzilumab, AMG 176, Azacitidine, Pevonedistat, Decitabine, 5-Azacitidine, Tipifarnib, and others.
- December 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for MBG453 and Azacitidine. This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line setting and are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator.
- December 2023: Merck Sharp & Dohme LLC announced a study of Phase 1 clinical trials for MK-0482. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated titration design (ATD) for participants with relapsed/refractory (R/R) AML or CMML. Part 2 is a dose expansion for participants with R/R AML.
Request a sample and discover the recent advances in Chronic Myelomonocytic Leukaemia Treatment Drugs @ Chronic Myelomonocytic Leukaemia Pipeline Outlook Report
The Chronic Myelomonocytic Leukaemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Chronic Myelomonocytic Leukaemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Chronic Myelomonocytic Leukaemia clinical trial landscape.
Chronic Myelomonocytic Leukaemia Overview
Chronic Myelomonocytic Leukaemia (CMML) is a rare type of blood cancer. CMML generally starts when a stem cell in the bone marrow mutates. This results in abnormal blood cell production and an overproduction of blasts and immature monocytes, types of white blood cells that crowd out other blood cells.
Find out more about Chronic Myelomonocytic Leukaemia Treatment Landscape @ Drugs for Chronic Myelomonocytic Leukaemia Treatment
Chronic Myelomonocytic Leukaemia Emerging Drugs Profile
- Sabatolimab: Novartis
- CFI-400945: Treadwell Therapeutics
- NMS-088: Nerviano Medical Sciences
- NC525: NextCure Inc.
Chronic Myelomonocytic Leukaemia Pipeline Therapeutics Assessment
There are approx. 25+ key Chronic Myelomonocytic Leukaemia companies which are developing Chronic Myelomonocytic Leukaemia therapies. The Chronic Myelomonocytic Leukaemia Companies which have their Chronic Myelomonocytic Leukaemia drug candidates in the most advanced stage, i.e. phase III include Novartis Pharmaceuticals.
DelveInsight’s Chronic Myelomonocytic Leukaemia pipeline report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Chronic Myelomonocytic Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Chronic Myelomonocytic Leukaemia Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Learn more about the emerging Chronic Myelomonocytic Leukaemia Pipeline Therapies @ Chronic Myelomonocytic Leukaemia Clinical Trials Assessment
Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report
- Coverage- Global
- Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Chronic Myelomonocytic Leukaemia Companies- Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc., and others.
- Chronic Myelomonocytic Leukaemia Pipeline Therapies- lenzilumab, AMG 176, Azacitidine, Pevonedistat, Decitabine, 5-Azacitidine, Tipifarnib, and others.
Dive deep into rich insights for new drugs for Chronic Myelomonocytic Leukaemia treatment, Visit @ Chronic Myelomonocytic Leukaemia Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Chronic Myelomonocytic Leukaemia: Overview
- Chronic Myelomonocytic Leukaemia Pipeline Therapeutics
- Chronic Myelomonocytic Leukaemia Therapeutic Assessment
- Chronic Myelomonocytic Leukaemia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- MBG453: Novartis Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- CFI-400945: Treadwell Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Myelomonocytic Leukaemia Companies
- Chronic Myelomonocytic Leukaemia Key Products
- Chronic Myelomonocytic Leukaemia Unmet Needs
- Chronic Myelomonocytic Leukaemia Market Drivers and Barriers
- Chronic Myelomonocytic Leukaemia- Future Perspectives and Conclusion
- Chronic Myelomonocytic Leukaemia Analyst Views
- Chronic Myelomonocytic Leukaemia Companies
- Appendix
For further information on the Chronic Myelomonocytic Leukaemia pipeline therapeutics, reach out to Chronic Myelomonocytic Leukaemia Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market